Patient baseline demographics and clinical/disease characteristics
| Characteristic . | Total, intent-to-treat cohort (N = 27) . |
|---|---|
| Median age (range), y | 67 (47-78) |
| ≥65, n (%) | 18 (66.7) |
| Median donor age (range), y | 28 (20-64) |
| Patient sex, n (%) | |
| Female | 10 (37) |
| Male | 17 (63) |
| Donor sex, n (%) | |
| Female | 11 (40.7) |
| Male | 16 (59.3) |
| Male patient, female donor, n (%) | 4 (14.8) |
| ECOG performance status, n (%) | |
| 0 | 6 (22.2) |
| 1 | 12 (44.4) |
| 2 | 9 (33.3) |
| HCT-CI, n (%) | |
| 1 | 8 (29.6) |
| 2-3 | 4 (14.8) |
| ≥4 | 15 (55.6) |
| Median (range) | 4 (1-10) |
| Histology, n (%) | |
| MDS | 16 (59.3) |
| AML | 10 (37) |
| MDS/MPN | 1 (3.7) |
| Disease risk index | |
| Intermediate | 9 (33.3) |
| High | 17 (63) |
| Very high | 1 (3.7) |
| Number of prior therapies, median (range) | 1 (0-3) |
| Prior Ven exposure, n (%) | 15 (55.6) |
| Flow MRD positivity, n (%) | 15 (55.6) |
| TP53 mutation, n (%) | |
| No | 11 (40.7) |
| Yes | 16 (59.3) |
| HLA molecular typing (A, B, C, and DRB1), n (%) | |
| Matched related | 3 (11.1) |
| Matched unrelated | 24 (88.9) |
| Patient and donor CMV serostatus | |
| Negative/negative | 12 (44.4) |
| Negative/positive | 6 (22.2) |
| Positive/negative | 5 (18.5) |
| Positive/positive | 4 (14.8) |
| Characteristic . | Total, intent-to-treat cohort (N = 27) . |
|---|---|
| Median age (range), y | 67 (47-78) |
| ≥65, n (%) | 18 (66.7) |
| Median donor age (range), y | 28 (20-64) |
| Patient sex, n (%) | |
| Female | 10 (37) |
| Male | 17 (63) |
| Donor sex, n (%) | |
| Female | 11 (40.7) |
| Male | 16 (59.3) |
| Male patient, female donor, n (%) | 4 (14.8) |
| ECOG performance status, n (%) | |
| 0 | 6 (22.2) |
| 1 | 12 (44.4) |
| 2 | 9 (33.3) |
| HCT-CI, n (%) | |
| 1 | 8 (29.6) |
| 2-3 | 4 (14.8) |
| ≥4 | 15 (55.6) |
| Median (range) | 4 (1-10) |
| Histology, n (%) | |
| MDS | 16 (59.3) |
| AML | 10 (37) |
| MDS/MPN | 1 (3.7) |
| Disease risk index | |
| Intermediate | 9 (33.3) |
| High | 17 (63) |
| Very high | 1 (3.7) |
| Number of prior therapies, median (range) | 1 (0-3) |
| Prior Ven exposure, n (%) | 15 (55.6) |
| Flow MRD positivity, n (%) | 15 (55.6) |
| TP53 mutation, n (%) | |
| No | 11 (40.7) |
| Yes | 16 (59.3) |
| HLA molecular typing (A, B, C, and DRB1), n (%) | |
| Matched related | 3 (11.1) |
| Matched unrelated | 24 (88.9) |
| Patient and donor CMV serostatus | |
| Negative/negative | 12 (44.4) |
| Negative/positive | 6 (22.2) |
| Positive/negative | 5 (18.5) |
| Positive/positive | 4 (14.8) |
CMV, cytomegalovirus; ECOG, Eastern Cooperative Oncology Group; HCT-CI, hematopoietic cell transplantation–specific comorbidity index.